JP2020520948A - 心不全の治療用のホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）アゴニストの新規な使用 - Google Patents

心不全の治療用のホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）アゴニストの新規な使用 Download PDF

Info

Publication number
JP2020520948A
JP2020520948A JP2019564446A JP2019564446A JP2020520948A JP 2020520948 A JP2020520948 A JP 2020520948A JP 2019564446 A JP2019564446 A JP 2019564446A JP 2019564446 A JP2019564446 A JP 2019564446A JP 2020520948 A JP2020520948 A JP 2020520948A
Authority
JP
Japan
Prior art keywords
compound
heart failure
treatment
weeks
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019564446A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020520948A5 (enExample
Inventor
ジャセク・オストロウスキー
リカルド・ガルシア
ニコラス・アール・ワーツ
ナンシー・リー・カーソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62567841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2020520948(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2020520948A publication Critical patent/JP2020520948A/ja
Publication of JP2020520948A5 publication Critical patent/JP2020520948A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2019564446A 2017-05-22 2018-05-22 心不全の治療用のホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）アゴニストの新規な使用 Pending JP2020520948A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762509489P 2017-05-22 2017-05-22
US62/509,489 2017-05-22
PCT/US2018/033783 WO2018217684A1 (en) 2017-05-22 2018-05-22 Novel use of a formyl peptide receptor 2/ lipoxin a4 receptor (fpr2/alx) agonist for treatment of heart failure

Publications (2)

Publication Number Publication Date
JP2020520948A true JP2020520948A (ja) 2020-07-16
JP2020520948A5 JP2020520948A5 (enExample) 2021-07-26

Family

ID=62567841

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019564446A Pending JP2020520948A (ja) 2017-05-22 2018-05-22 心不全の治療用のホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）アゴニストの新規な使用

Country Status (15)

Country Link
US (1) US20200069644A1 (enExample)
EP (1) EP3630097A1 (enExample)
JP (1) JP2020520948A (enExample)
KR (1) KR20200006595A (enExample)
CN (1) CN110662538A (enExample)
AU (1) AU2018273382A1 (enExample)
BR (1) BR112019024185A2 (enExample)
CA (1) CA3064291A1 (enExample)
CL (1) CL2019003325A1 (enExample)
CO (1) CO2019013015A2 (enExample)
EA (1) EA201992704A1 (enExample)
IL (1) IL270749A (enExample)
MX (1) MX2019013926A (enExample)
PE (1) PE20200402A1 (enExample)
WO (1) WO2018217684A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023546371A (ja) * 2020-10-09 2023-11-02 ブリストル－マイヤーズ スクイブ カンパニー アミノイミダゾールｆｐｒ２アゴニスト

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2869129T3 (es) * 2017-06-09 2021-10-25 Bristol Myers Squibb Co Agonistas de piperidinona del receptor 2 de péptidos formilados
JP7700210B2 (ja) 2020-07-09 2025-06-30 ブリストル－マイヤーズ スクイブ カンパニー ピラゾロンホルミルペプチド２受容体アゴニスト
JP7802765B2 (ja) 2020-08-12 2026-01-20 ブリストル－マイヤーズ スクイブ カンパニー オキソピロリジン尿素ｆｐｒ２アゴニスト
CN119055775A (zh) * 2022-07-30 2024-12-03 中国医学科学院阜外医院 Jun抑制剂在制备用于治疗射血分数保留的心衰的药物中的用途
CN118831080B (zh) * 2024-09-24 2024-11-22 上海交通大学医学院附属仁济医院 5-氧脯氨酸在制备预防或治疗心肌病的药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005536187A (ja) * 2002-04-03 2005-12-02 バイエル・ヘルスケア・アクチェンゲゼルシャフト Ｎ−ホルミルペプチド受容体様１（ｆｐｒｌ１）に関連する疾患の診断および治療
WO2015079692A1 (ja) * 2013-11-28 2015-06-04 杏林製薬株式会社 ウレア誘導体、またはその薬理学的に許容される塩

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101645015B1 (ko) * 2014-03-11 2016-08-03 포항공과대학교 산학협력단 Fpr2를 활성화하는 물질을 포함하는, 인슐린 저항성 관련 질환 치료용 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005536187A (ja) * 2002-04-03 2005-12-02 バイエル・ヘルスケア・アクチェンゲゼルシャフト Ｎ−ホルミルペプチド受容体様１（ｆｐｒｌ１）に関連する疾患の診断および治療
WO2015079692A1 (ja) * 2013-11-28 2015-06-04 杏林製薬株式会社 ウレア誘導体、またはその薬理学的に許容される塩

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023546371A (ja) * 2020-10-09 2023-11-02 ブリストル－マイヤーズ スクイブ カンパニー アミノイミダゾールｆｐｒ２アゴニスト
JP7855580B2 (ja) 2020-10-09 2026-05-08 ブリストル－マイヤーズ スクイブ カンパニー アミノイミダゾールｆｐｒ２アゴニスト

Also Published As

Publication number Publication date
WO2018217684A1 (en) 2018-11-29
AU2018273382A1 (en) 2020-01-16
US20200069644A1 (en) 2020-03-05
CL2019003325A1 (es) 2020-04-17
PE20200402A1 (es) 2020-02-26
CN110662538A (zh) 2020-01-07
IL270749A (en) 2020-01-30
CO2019013015A2 (es) 2020-01-17
CA3064291A1 (en) 2018-11-29
EP3630097A1 (en) 2020-04-08
EA201992704A1 (ru) 2020-03-19
BR112019024185A2 (pt) 2020-06-02
MX2019013926A (es) 2020-01-20
KR20200006595A (ko) 2020-01-20

Similar Documents

Publication Publication Date Title
US20200069644A1 (en) Novel use of a formyl peptide receptor 2/ lipoxin a4 receptor (fpr2/alx) agonist for treatment of heart failure
US12295952B2 (en) Methods of treating heart failure with cardiac sarcomere activators
JP2018016647A (ja) 新規方法
JP3838065B2 (ja) 肺高血圧の治療剤
US20110190277A1 (en) Pharmaceutical combination for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases
KR20250050043A (ko) 비폐쇄성 비대심근병증 치료 방법
AU2022299103B2 (en) Methods of using aldosterone synthase inhibitors
KR20250056200A (ko) 폐쇄성 비대심장근육병증 치료 방법
JP2016041766A (ja) 急性心不全の治療のための方法および組成物
CN114072205A (zh) 用tie-2激活剂治疗高血压的方法
TW202245781A (zh) 用維貝格龍（ｖｉｂｅｇｒｏｎ）治療心臟衰竭之方法
KR20200062240A (ko) 시포니모드의 투여 요법
JP6688503B2 (ja) 医薬用組成物
KR20240021827A (ko) 미토콘드리아 관련 장애를 치료하는 방법
US20160101117A1 (en) Use of Megestrol Acetate for Improving Heart Function and the Treatment of Heart Insufficiency
US20240366596A1 (en) Treatment of hfpef in post-menopausal women with an sgc stimulator
SK19332001A3 (sk) Použitie antagonistov kortizolu v liečení srdcového zlyhania
JP2025513337A (ja) 心原性ショック前および心原性ショックの処置のためのイスタロキシムを含む静脈内注入製剤
TW201904584A (zh) 減少或預防第ｉｉ型糖尿病患者中心血管事件之方法
US20210393592A1 (en) Pharmaceutical composition for use in treatment of hypertrophic cardiomyopathy
WO2025198687A1 (en) Methods for treating heart diseases
WO2024260354A1 (zh) 一种蓓萨罗丁药物共晶及其制备方法和用途
Dron et al. Effect of L-Arginine on pathogenetic mechanisms of hypertension formation in both the pulmonary and systemic circulations of patients with arterial hypertension and co-existent pulmonary hypertension of bronchopulmonary origin
HK40063597A (en) Methods of treating hypertension with activators of tie-2
JPWO2002064143A1 (ja) 慢性心不全治療用医薬組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210519

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210519

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220301

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221004